Skip to content

Perichondrium Autograft in Refractory Necrotizing Scleritis

Autologous Perichondrium Transplantation for Replacement of Stem Cells and Their Niche in the Treatment of Necrotizing Scleritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02864823
Acronym
PCRNS
Enrollment
20
Registered
2016-08-12
Start date
2011-03-31
Completion date
2016-06-30
Last updated
2016-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotizing Scleritis

Keywords

Scleromalacia perforans, Necrotizing Scleritis, Perichondrium

Brief summary

Necrotizing scleritis with severe ischemia is refractory to conventional treatment because of avascular necrosis. The investigators assessed the therapeutic efficacy and safety of autologous perichondrium transplantation in patients with severe ischemic necrotizing scleritis, and analyzed the therapeutic effects.

Detailed description

Ischemic necrotizing scleritis patients who showed persistent and progressive scleral melting were included in this study. Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect after the necrotic tissue removal.

Interventions

PROCEDUREPerichondrium Autografts

Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.

Sponsors

Ministry of Science and ICT, Republic of Korea
CollaboratorOTHER_GOV
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. impending perforation or perforation state of sclera; 2. graft melting following previous surgery; 3. bacterial or fungal infection of sclera or graft after previous surgery; 4. discomfort due to protrusion of scleral calcification with ischemic necrosis 5. broad avascular area larger than 10 mm in diameter

Exclusion criteria

1. asymptomatic patients 2. smaller scleral defect less than 10 mm in diameter 3. shallow scleral defect

Design outcomes

Primary

MeasureTime frameDescription
Success Rate of Repair of Scleral DefectsSix months after reconstructive surgerySuccess Rate of Repair of Scleral Defects

Secondary

MeasureTime frame
Post-Operative ComplicationsSix months after reconstructive surgery

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026